Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Reports Discovery of Biomarker Pattern for Alzheimer s Disease

NEW YORK, Nov. 10 (GenomeWeb News) - Ciphergen Biosystems said today that it has discovered a biomarker pattern that correctly classified more than 96 percent of Alzheimer's disease patents and more than 94 percent of normal individuals using a four peak pattern of markers.


The company said the findings were presented at the Society for Neuroscience's annual meeting in New Orleans.


Ciphergen said that researchers analyzed cerebrospinal fluid from probable Alzheimer's diease pateints and age-matched normal individuals using the company's SELDI ProteinChip biomarker system and Expression Difference Mapping methodology.


Of the 39 candidate biomarkers found to be overexpressed among the Alzheimer's disease sufferers, a pattern of four was selected and used to correctly classify 29 of out 30 Alzheimer's disease patients and 33 of 35 normal individuals.


Ciphergen said that additional studies looking at more than 200 additional samples are underway to validate the markers' utility in diagnosing early-stage Alzheimer's disease and differentiating the condition from other dementias. 


The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.